1. What Is the Biosimilar Market?
The Biosimilar Market covers the biologic medicines that are demonstrated to be highly similar to the reference biologic product that the originator manufacturer marketed after patent and exclusivity expiry. Biosimilars have no clinically meaningful differences in safety, purity, and potency compared to the reference biologic. They provide the competition that reduces the price and increases access to biologic therapies that the specialty drug market prices at tens of thousands to hundreds of thousands of dollars annually. Biosimilar development requires the extensive analytical characterisation of the biosimilar's structural, functional, and clinical similarity to the reference biologic, pharmacokinetic and pharmacodynamic equivalence studies, and clinical safety and immunogenicity data. The extrapolation of indications across the reference biologic's approved indications does not require repeating the full clinical efficacy trial for each indication. The adalimumab biosimilar market in the United States following the expiry of the Humira 2023 exclusivity generated the entry of over 10 adalimumab biosimilars from multiple manufacturers. These are competing on net price and formulary access for the USD 20 billion adalimumab market, representing the largest single biosimilar market opportunity and demonstrating the disruptive pricing that biosimilar competition delivers.
2. Biosimilar Market Size & Forecast
3. Emerging Technologies
- Interchangeable biosimilar designation from FDA allows the pharmacist to substitute the interchangeable biosimilar for the reference biologic without prescriber intervention in the states that permit automatic substitution. Standard biosimilar designation requires the prescriber's active choice for the brand-to-biosimilar switch, while interchangeable designation bypasses this in permitting states. The interchangeability pathway is therefore the higher-value regulatory outcome that biosimilar manufacturers pursue for market penetration.
- Adalimumab biosimilar US market dynamics saw multiple biosimilar manufacturers enter at 5 to 85 percent list price discounts to Humira and compete for PBM formulary preferred positioning through rebate contracts. Each biosimilar manufacturer negotiates with the PBM for the formulary access that determines the covered population's access to the preferred adalimumab biosimilar. The competition across ten-plus biosimilar entrants has demonstrated the range of discount strategies available in a crowded biosimilar market.
- European biosimilar market maturity provides the 10-year head start on the US market where the EMA biosimilar pathway has been in operation since 2006. Competitive infliximab, etanercept, and rituximab biosimilar markets have achieved 40 to 70 percent price reductions that the European hospital market has adopted aggressively. Prescriber brand loyalty and payer rebate complexity have slowed biosimilar market share uptake in the US market relative to Europe despite the price savings available.
- Biosimilar immunogenicity monitoring requirement from the post-marketing pharmacovigilance that FDA and EMA impose on the approved biosimilar detects the anti-drug antibody development that the biosimilar's minor structural differences from the reference biologic might produce. A small proportion of patients who switch from the reference biologic may develop immunogenicity responses that ongoing safety surveillance is designed to detect early. Post-marketing safety data is a regulatory requirement for all approved biosimilars and is distinct from the pre-approval clinical immunogenicity data package.
Similar technologies are also transforming adjacent markets. Learn more in our Biopharmaceutical Market.
4. Key Market Opportunity
Substantial growth potential in the Biosimilar market is the oncology biosimilar pipeline, where approvals for checkpoint inhibitor and ADC biosimilars as patents expire create large commercial opportunities in high-revenue oncology categories. Manufacturers with biosimilar oncology capability capture this next wave. Additional momentum is centered on payer-driven formulary substitution creating rapid adoption. As oncology biosimilar entries accumulate and payer adoption strategies mature, the addressable opportunity is expanding from autoimmune biosimilars toward oncology category biosimilar penetration.
5. Top Companies in the Biosimilar Market
The following organisations hold leading positions in the Biosimilar Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Sandoz
- Pfizer
- Amgen
- Celltrion
- Samsung
- Biocon
- Teva Pharmaceutical
- Coherus BioSciences
- Viatris
- Alvotech
- Henlius
- Bio-Thera Solutions
- Fresenius Kabi
- Stada Arzneimittel
- Polpharma Biologics
6. Market Segmentation
The Biosimilar Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product | Monoclonal Antibody BiosimilarRecombinant ProteinInsulinErythropoietin |
| By Therapy | OncologyAutoimmuneDiabetesNephrology |
| By Distribution | Retail PharmacyHospitalInfusion Centre |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Biosimilar Market trajectory over the forecast period:
FDA Interchangeable Biosimilar Designation Enabling Pharmacist Substitution Without Prescriber Authorisation Is the Regulatory Status That Enables the Automatic Substitution That Biosimilar Market Penetration Requires Without Active Brand-to-Biosimilar Prescriber Switching.The January 2023 US adalimumab patent cliff triggered seven simultaneous biosimilar launches including Amgen's Amjevita, Pfizer's Abrilada, Samsung Bioepis's Hadlima, and Sandoz's Hyrimoz, achieving 40-plus percent biosimilar volume market share within 12 months. Interchangeability designations for Amgen's Amjevita and Sandoz's Hadlima enabled pharmacist-level substitution, and payer formulary placement of preferred biosimilars as step therapy before originator Humira accelerated market share transfer. The adalimumab experience is informing biosimilar launch strategies for ustekinumab and vedolizumab approaching patent expiry, with developers investing in interchangeability data packages and biosimilar-specific patient-switching support programmes.
Ten-Plus Adalimumab Biosimilars Entering US Market With 5 to 85 Percent List Price Discounts Competing for PBM Formulary Preference Has Created the Largest Single Biosimilar Market Competition That Has Demonstrated Biologic Pricing Disruption at Scale.Trastuzumab biosimilars from Pfizer, Amgen, Biocon-Mylan, and Samsung Bioepis collectively achieved over 80% US market share by 2024, representing the commercially successful oncology biosimilar transition and generating estimated USD 5-7 billion in healthcare system savings versus originator Herceptin pricing. Bevacizumab biosimilars from Pfizer Zirabev, Amgen Mvasi, and Samsung Bioepis Aybintio similarly achieved rapid share gains in colorectal and lung cancer standard regimens. The oncology biosimilar evidence base from trastuzumab and bevacizumab switching studies is informing prescriber confidence for rituximab, pertuzumab, and pembrolizumab biosimilar prescribing as the next patent wave expires through 2028-2032.
European Biosimilar Market 10-Year Head Start Achieving 40 to 70 Percent Price Reductions in Infliximab and Rituximab Has Established the Competitive Market Maturity Benchmark That the US Biosimilar Market Is Progressing Toward Despite Rebate Complexity Slowing Adoption.Merck's pembrolizumab Keytruda generates USD 25-plus billion annually, and the patent expiry timeline extending to 2028-2033 is driving early biosimilar development from Alvotech, Formycon, and Biocon representing the single commercially significant biosimilar opportunity in pharmaceutical development at an estimated USD 15-20 billion annual market. Regeneron's dupilumab Dupixent at USD 11-plus billion annually represents the second-largest biosimilar opportunity, with 2031-the mid-2030s EU and US patent expiry timelines driving investment from Samsung Bioepis, Alvotech, and Formycon. Biosimilar development cost for complex antibody products has fallen from approximately USD 200 million to USD 80-150 million as analytical platform standardisation and clinical data package acceptance criteria have been clarified through FDA and EMA guidance.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By product, the adalimumab biosimilar segment dominated the Biosimilar Market in 2025, as products from Amgen, Sandoz, Celltrion, and Alvotech captured quickly growing market share following Humira's loss of exclusivity, generating the largest single-originator biosimilar revenue across the major markets.
By therapy area, the oncology biosimilar segment is projected to register the highest growth rate through 2034, as biosimilar trastuzumab and bevacizumab from Biocon and Samsung Bioepis expand access to high-cost targeted cancer therapies across all major markets.
9. Regional Analysis
Regional demand patterns across the Biosimilar Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
Europe dominated the Biosimilar Market in 2025, accounting for approximately 27% of global revenue, attributed to Europe's earlier biosimilar regulatory framework through the EMA and the established biosimilar substitution in major European healthcare systems including Germany and France. Moreover, the European market adopted adalimumab and other biosimilars before the US, creating the most mature substitution environment. In addition, public tender systems in Europe drive biosimilar formulary preference. Regional leadership is due to this combination of regulatory maturity and substitution infrastructure.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Biosimilar Market through 2034, driven by biosimilar adoption in China and India where the large patient populations and cost-sensitive payer environments make biosimilar penetration economically compelling. The region is also witnessing domestic biosimilar manufacturing investment growing. Moreover, regulatory approvals for biosimilars in regional markets are expanding. The combination of these demand drivers and manufacturing investment positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Biosimilar Market was valued at USD 39.66 Bn in 2025 and is projected to reach USD 134.15 Bn by 2034, growing at a CAGR of 14.5% over the 2026–2034 forecast period.
The Biosimilar Market is projected to grow at a CAGR of 14.5% from 2026 to 2034.
Europe dominated the Biosimilar Market in 2025, accounting for approximately 27% of global revenue, attributed to Europe's earlier biosimilar regulatory framework through the EMA and the established biosimilar substitution in major European healthcare systems including Germany and France.
The leading companies in the Biosimilar Market include Sandoz, Pfizer, Amgen, Celltrion, Samsung, Biocon, Teva Pharmaceutical, Coherus BioSciences, Viatris, Alvotech, Henlius, Bio-Thera Solutions, Fresenius Kabi, Stada Arzneimittel, Polpharma Biologics.
Fda interchangeable biosimilar designation enabling pharmacist substitution without prescriber authorisation is the regulatory status that enables the automatic substitution that biosimilar market penetration requires without active brand-to-biosimilar prescriber switching.
By product, the adalimumab biosimilar segment dominated the Biosimilar Market in 2025, as products from Amgen, Sandoz, Celltrion, and Alvotech captured quickly growing market share following Humira's loss of exclusivity, generating the largest single-originator biosimilar revenue across the major markets.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.